AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04508257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral feeding of Investigational Formula (Stage 1&2)
Description: Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.
Study NCT04508257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral feeding of Control formula (Stage 1&2)
Description: Participants will receive stage 1 formulas up to 180 days of age and then switch to stage 2 formulas though 365 days of age.
Study NCT04508257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Breast feeding
Description: Exclusively breastfed for the first 4 months and continue with supplement food without any marketed infant formula.
Study NCT03711942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Base
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.2mm thick Base of GIC was applied over the orifice before composite restoration
Study NCT03711942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.coronal accees upto orifice was restored with composite resin
Study NCT03711942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.coronal accees upto orifice was restored with composite resin
Study NCT03648320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Description: Daily doses of peanut flour (with 2-weekly incremental interval)
Study NCT04744064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein and carbohydrate
Description: Intake of 2 x 250 ml of either protein (750 KJ, 21.0 g protein (milk protein), 15.0 g carbohydrate, 4.5 g fat ) or carbohydrate ( 750 KJ, 0 g protein, 0 g fat and 49.2 g carbohydrate (2:1 ratio of maltodextrin: fructose))
Study NCT04348344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Patients receive health education of pulmonary rehabilitation, using the home-based rehabilitation exercise prescription, taking home exercise as the main form, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training: walking, intermittent strength training: elastic band and inspiratory muscle training:apparatus, abdominal breathing training.
Study NCT01973842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1 mg triptorelin
Study NCT01973842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2 mg triptorelin
Study NCT02453932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianzhi granule and placebo identified to donepezil
Description: 1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks
Study NCT01973842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.4 mg triptorelin
Study NCT02112422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
Study NCT02112422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
Study NCT01284569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Description: Intravenous administration, single dose (0.3-1-3-6-8 mg/kg) or multiple dose (Biologically effective dose, once every 4 weeks or once every 8 weeks, for 24 weeks)
Study NCT01284569 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration, single dose or multiple dose (once every 4 weeks or once every 8 weeks, for 12(/24) weeks; switch to ALX-0061 in weeks 13-24 if no response after first 12 weeks)
Study NCT04175652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: The laughter yoga practice was initiated through clapping and warm-up exercises: hands were clapped keeping hands in parallel with each other and ensuring that the fingertips touched each other. To increase the energy level of the group, a rhythmic beat was added to the clapping in the form of 1-2, 1-2-3. While this was being sung a rhythm was tapped out on the floor by moving the feet up and down. Eye contact was constantly maintained with the participants. In the second phase, deep breathing exercises were performed. Participants were encouraged to inhale from the diaphragm. Individuals were asked to put their hands on their belly and inhale through the nose and then slowly exhale through the mouth. After the deep breathing exercise, the participants were encouraged to laugh through playing children's games in the third phase.
Study NCT02850445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.
Study NCT02850445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.
Study NCT02850445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Cognitive behavioral therapy.
Study NCT02850445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Description: Rehabilitation treatment include three modules: medication management, symptom management, and social kill training. Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Rehabilitation treatment therapy.
Study NCT02850445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management
Description: Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Case management.
Study NCT01804192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acu-TENS
Description: Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.
Study NCT01804192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acu-TENS
Description: Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.
Study NCT01804192 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acu-TENS
Description: Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.
Study NCT01854073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine butyl bromide
Study NCT02453932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil and placebo identified to Tianzhi granule
Description: donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks
Study NCT02453932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks
Study NCT00848718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 given by mouth (PO) on Days 1, 3, 5, and 7 of each 21-day cycle (30 mg, 45 mg, or 60 mg) OR MK-2206 PO on Day 1 of each 21-day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg)
Study NCT00848718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Administered as an IV infusion on Day 1 of each 21-day cycle
Study NCT00848718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Administered daily (QD) PO in each 21-day cycle
Study NCT00848718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
Study NCT00848718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
Study NCT00848718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid
Description: Administered PO twice a day (BID) on Days 1-3 of each 21-day cycle
Study NCT04287075 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical Management of Neuroma
Description: Surgical procedures targeted to treat the source of a participant's chronic, neuropathic pain
Study NCT04197466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Exercise Group
Description: The exercise program will be tailored according to the pelvic floor muscle strength, including fast and slow contractions. The number and duration of exercises will be increased according to progress..
Study NCT04036916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Sensorimotor Training
Description: Games/activities specifically developed to train the sensorimotor system in headset virtual reality + strengthening of the neck
Study NCT00233935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT00233935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given PO
Study NCT00407537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/atorvastatin calcium single pill combination
Description: Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
Study NCT01248650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nalfurafine hydrochloride
Study NCT02682264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-01 cream, 1%
Description: Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
Study NCT02667158 — intervention group
Intervention type: OTHER
Intervention: Survey to Eval Relation between Shopping and Misuse, Abuse
Description: A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
Study NCT00971048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HP828-101
Description: Topical test article applied once daily
Study NCT00971048 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel/Hydrocolloid
Description: Hydrogel for DFU and Hydrocolloid for PU (3M Tegaderm Hydrogel for DFU; ConvaTec DuoDERM Hydroactive Gel for PU); Topical test articles applied once daily
Study NCT02169687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: High Intensity focalized Ultrasounds
Study NCT01985594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: utrogestan
Description: Oral Tablet Utrogestan 400 mg daily for 2 days
Study NCT01985594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine
Description: Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days
Study NCT02078323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linaclotide
Study NCT02078323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02579941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling (non pregnant)
Description: 5.4 ml of venous blood will be taken.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM.
Study NCT01112371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contractubex
Description: Contractubex® Gel, containing 10% extractum cepae, 1% allantoin and 50/U of sodium heparin per one gram of gel.~Active drug group: The gel will be applied twice daily (morning/evening). Approximately 2 cm of the IMP are applied onto the scar by light massage rubbing carefully until the product is worked in.
Study NCT03392688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kujala patellofemoral pain scale
Description: Kujala patellofemoral pain scale was used to evaluate knee functions of the PFP subjects.
Study NCT03392688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Surface EMG
Description: The surface EMG electrodes (silver/silver chloride, pre-gelled, Ambu Blue Sensor, Denmark) (Konrad P.) with an interelectrode distance of 20 mm between centers were used to record an EMG signal during walking. Portable 8 channel (TELEEMG, BTS, Milan, Italy) with built in x10 amplifications, 10-450 Hz bandpass and sampling rate of 1000 Hz were used for recording. The location and orientation of the electrodes for each MH (ST) and LH (BF) were identified according to SENIAM (Surface ElectromyoGraphy for the Non-Invasive Assessment of Muscles) criteria.
Study NCT03392688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Surface EMG
Description: The surface EMG electrodes (silver/silver chloride, pre-gelled, Ambu Blue Sensor, Denmark) (Konrad P.) with an interelectrode distance of 20 mm between centers were used to record an EMG signal during walking. Portable 8 channel (TELEEMG, BTS, Milan, Italy) with built in x10 amplifications, 10-450 Hz bandpass and sampling rate of 1000 Hz were used for recording. The location and orientation of the electrodes for each MH (ST) and LH (BF) were identified according to SENIAM (Surface ElectromyoGraphy for the Non-Invasive Assessment of Muscles) criteria.
Study NCT03392688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Q angle measurement
Description: Q angle measurement was applied to both patellofemoral pain and control group subjects in standing position.
Study NCT03392688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Q angle measurement
Description: Q angle measurement was applied to both patellofemoral pain and control group subjects in standing position.
Study NCT04197466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Kinesio tape application will be performed by ligament technique to the sacral region.
Study NCT04197466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: External electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
Study NCT04955353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AVC-H2
Description: A total of 2.5g AVC-H2 daily (2 tablets in the morning and 2 in the evening)
Study NCT04955353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 2.5g placebo daily (2 tablets in the morning and 2 in the evening)
Study NCT02999750 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: individual therapy
Description: Patient will be treated with individual therapy.
Study NCT01315392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: delayed closure
Description: wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for a second debridement and definitive closure.
Study NCT01854073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT04407468 — intervention group
Intervention type: PROCEDURE
Intervention: Prone position
Description: Position of the patient in which he is face down, for an improvement in oxygenation
Study NCT01148680 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Islet Graft
Description: Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
Study NCT01315392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate wound closure
Description: traumatic and surgical wounds closed at the initial surgical intervention
Study NCT04483830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulodexide
Description: an oral dose of 2 capsules each day for 21 days
Study NCT04483830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an oral dose of 2 capsules each day for 21 days
Study NCT02809729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: 2 g of cefazolin diluted in 0.9% saline by endovenous, once, at the moment of anesthetic induction
Study NCT02809729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline
Description: 0.9% saline sterile by endovenous, once, at the moment of anesthetic induction
Study NCT02809729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oncologic breast surgery
Description: The patient will be submitted to a conservative oncologic breast surgery
Study NCT02809729 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: oncologic breast surgery
Description: The patient will be submitted to a conservative oncologic breast surgery
Study NCT02809729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microbiology
Description: Samples for quantitative cultures will be obtained in the operating room before antisepsis and the end of surgery. A sample is also collected with the same patterning, on the first postoperative day, immediately after the removal of the dressing placed in the operating room. Will be passed in a standardized manner, a sterile swab soaked in saline over a standard 5cm by 10cm area determined by a field fenestrated sterile filter paper.
Study NCT02809729 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microbiology
Description: Samples for quantitative cultures will be obtained in the operating room before antisepsis and the end of surgery. A sample is also collected with the same patterning, on the first postoperative day, immediately after the removal of the dressing placed in the operating room. Will be passed in a standardized manner, a sterile swab soaked in saline over a standard 5cm by 10cm area determined by a field fenestrated sterile filter paper.